Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

1. Aroda, V.R.
2. Ahmann, A.
3. Cariou, B.
4. Chow, F.
5. Davies, M.J.
6. Jódar, E.
7. Mehta, R.
8. Woo, V.
9. Lingvay, I.